Martin S Rhee
Overview
Explore the profile of Martin S Rhee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramgopal M, Mezzio D, Dunn K, Liu S, Paul D, Rhee M, et al.
AIDS Behav
. 2025 Mar;
PMID: 40063206
Lenacapavir, a first-in-class inhibitor of HIV-1 capsid function, can be administered twice yearly subcutaneously (SC). In the ongoing Phase 2/3 CAPELLA study (NCT04150068), the addition of SC lenacapavir to an...
2.
Ogbuagu O, Avihingsanon A, Segal-Maurer S, Wang H, Jogiraju V, Singh R, et al.
AIDS
. 2025 Feb;
PMID: 39912752
Objective: To assess efficacy, safety and pharmacokinetics (PK) of oral lenacapavir (LEN) when used as oral bridging (OB) between delayed subcutaneous (SC) LEN injections. Design: Posthoc analysis of participants in...
3.
Margot N, Jogiraju V, Pennetzdorfer N, Naik V, VanderVeen L, Ling J, et al.
J Infect Dis
. 2025 Jan;
PMID: 39873394
Background: Lenacapavir is a highly potent first-in-class inhibitor of HIV-1 capsid approved for the treatment of heavily treatment-experienced (HTE) people with HIV-1 (PWH) harboring multidrug resistant (MDR) virus, in combination...
4.
Singh R, Shelton M, Olson I, Ling J, West S, Levy J, et al.
Clin Pharmacol Drug Dev
. 2025 Jan;
PMID: 39844693
Lenacapavir is a potent, long-acting HIV-1 capsid inhibitor used in combination with other antiretrovirals to treat HIV-1 infection. The pharmacokinetics of orally administered drugs may be affected by food intake...
5.
Ogbuagu O, Molina J, Chetchotisakd P, Ramgopal M, Sanchez W, Brunetta J, et al.
Clin Infect Dis
. 2024 Aug;
PMID: 39206943
Background: Lenacapavir is a long-acting HIV-1 capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background regimen (OBR)...
6.
Murdock N, Alajaji N, Schaefer R, Boone C, Campo R, Dore G, et al.
Open Forum Infect Dis
. 2024 Jul;
11(7):ofae337.
PMID: 38983711
New long-acting HIV treatment products have the potential to change the HIV epidemic in the United States and globally. Phase 3 clinical trials of HIV treatments tend to underrepresent populations...
7.
Ogbuagu O, Segal-Maurer S, Ratanasuwan W, Avihingsanon A, Brinson C, Workowski K, et al.
Lancet HIV
. 2023 Jul;
10(8):e497-e505.
PMID: 37451297
Background: Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety of lenacapavir with...
8.
Chatzidaki I, Curteis T, Luedke H, Mezzio D, Rhee M, McArthur E, et al.
Value Health
. 2022 Dec;
26(6):810-822.
PMID: 36566886
Background/aims: Heavily treatment-experienced (HTE) people with human immunodeficiency virus (HIV) (PWH) may not achieve virologic suppression (VS) with combination antiretroviral therapy due to multidrug resistance (MDR), intolerance, and safety concerns....
9.
Gupta S, Berhe M, Crofoot G, Benson P, Ramgopal M, Sims J, et al.
Lancet HIV
. 2022 Dec;
10(1):e15-e23.
PMID: 36566079
Background: Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV. Lenacapavir, an inhibitor of capsid protein that makes use of a unique mechanism,...
10.
Margot N, Naik V, VanderVeen L, Anoshchenko O, Singh R, Dvory-Sobol H, et al.
J Infect Dis
. 2022 Sep;
226(11):1985-1991.
PMID: 36082606
Background: Lenacapavir (LEN) is a first-in-class inhibitor of human immunodeficiency virus type 1 (HIV-1) capsid function in clinical development for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH)...